Overview

Hypogonadotropic hypogonadism (HH) and anosmia are combined together in Kallmann's syndrome (KS). Anosmia, or the lack of smell, and tiny testes are the most common symptoms of KS, a genetically diverse developmental disorder. Depending on the hereditary type of the disease, there may also be certain non-reproductive non-olfactory abnormalities.

This condition, which was initially identified in the 20th century, involves a complicated interaction between genetic abnormalities that impact neuroendocrine control and neuronal migration. Infertility and delayed or missing puberty are just two of the many clinical indications of the illness, which is also commonly linked to other non-reproductive abnormalities.

Introduction

In 1856, Maestre de San Juan was the first to define Kallman's condition.^1,4 A rare kind of idiopathic hypogonadotropic hypogonadism, Kallmann's syndrome is characterised by an absent olfactory bulb and a reduced sense of smell.³ Cleft lip and cleft palate at birth are the two markers of Kallmann's syndrome. The disease is also known as olfactogenital dysplasia since anosmia has been linked to olfactory bulb agenesis.⁴

At least three distinct genetic abnormalities are responsible for the syndrome's transmission, which might be autosomal dominant, autosomal recessive, or X-linked.¹ A Kallmann gene found on X chromosome 1 appears to be responsible for at least part of the cases. 

After studying the incidence of hypogonadism and anosmia in three affected families, American medical geneticist Kallmann recognised the syndrome as a clinical entity in 1944.²

He demonstrated that anosmia and hypogonadism cosegregate in all afflicted individuals, proving that this syndrome may be inherited.

Due to its clinical resemblance to other types of delayed puberty and hypogonadotropic hypogonadism, Kallmann Syndrome is still difficult to diagnose. A complete clinical history is essential, with a focus on olfactory function and pubertal progression.

Etiology

This disease has both clinical and genetic heterogeneity. Its X chromosome-linked recessive form is caused by KAL1, which contains genes for the extracellular glycoprotein anosmin-1.

Mutations in FGFR1 or FGF8, which encode fibroblast growth factor receptor-1 and fibroblast growth factor-8, respectively, result in an autosomal dominant variation with partial penetrance.²

Less than 30% of KS patients have mutations in any of the KS genes listed above, suggesting that there are still unidentified genes causing the illness.

Autosomal dominant with incomplete penetrance, autosomal recessive, X chromosome-linked recessive, and most likely digenic/oligogenic inheritance are several ways that KS is transmitted. KAL1, FGFR1, FGF8, PROKR2, and proK2 were the five known disease genes with mutations in less than 30% of  patients.²

The patient's gender, any family history, the suspected mechanism of illness inheritance, and the existence of any additional clinical abnormalities that might point the geneticist in the direction of a specific disease gene or, in rare cases, a contiguous gene syndrome are the basis for the genetic testing technique.²

The developmental anomaly in KS is considered to be caused by mutations in a variety of genes, most notably KAL1, FGFR1, PROKR2, and PROK2, which are involved in neuronal migration and neuroendocrine development.
Deficient gonadotropin secretion and consequent reproductive failure are caused by these genetic abnormalities, which disrupt the normal location and activity of GnRH neurons in the hypothalamus. Furthermore, anosmia or hyposmia, which is still a defining characteristic of the disease, is a manifestation of the lack of olfactory nerve development.⁵

Prevalence

The estimated prevalence of the disease is 1 in 8000 for people assigned male at birth (AMAB) and 1 in 40,000 for people assigned female at birth (AFAB), although this may be understated, particularly for AFAB people.
It has been estimated to be one in 8,000 for children AMAB. Despite being projected to be five times lower, the frequency of AFAB in children is probably underestimated because some affected people with AFAB only have mild hypogonadism.²

Features

Due to the absence of olfactory lobes, Kallmann's disease has also been linked to holoprosencephaly.
In individuals with Kallmann's syndrome, mandibular inclination is shown to be elevated. In the dentition, agenesis is observed.¹

Deviation in craniofacial morphology is displayed by the patients; sagittally, the maxilla and mandible are more retrognathic, with increased mandibular inclination and the maxilla's vertical inclination. Both upper and lower incisor inclinations will be decreased.¹ Some patients have agenesis both outside and in the cleft area.

The connection between anosmia and hyposmia, Hypogonadotropic hypogonadism, and cleft lip and palate may be related to early embryonic development.

Abnormal eye movements, congenital ptosis, abnormal visual-spatial attention, hearing impairment, unilateral (sometimes bilateral) renal agenesis, cleft lip or palate, agenesis of one or more teeth (hypodontia), corpus callosum agenesis, and other less well-documented abnormalities are some of these conditions.²

These include midline deformities that indicate developmental disturbances during embryogenesis, including cleft lip and/or palate. Additionally, patients may exhibit facial asymmetry, high-arched palates, or dental agenesis.⁵
There have also been reports of skeletal anomalies such as syndactyly (webbing of the fingers or toes), clinodactyly (curvature of the digits), and pectus excavatum. The developmental relevance of these genetic pathways is reflected in the fact that 20–30% of KS cases have renal agenesis or unilateral renal hypoplasia, especially in those with FGFR1 mutations.⁵

The importance of early diagnosis and effective care is highlighted by the fact that chronic hypogonadism reduces peak bone mass accumulation, predisposing patients to osteopenia or osteoporosis later in life. Attention should also be paid to cognitive and psychosocial factors. Some patients struggle with infertility, delayed sexual development, and body image issues, all of which can exacerbate mood disorders or psychological distress. Though less frequently highlighted, neurocognitive abnormalities can include mild deficiencies in executive function or visuospatial skills, highlighting the need for thorough assessment and assistance.⁵

Due to the absence of sexual development, which is indicated by small testes and missing virilisation in males or by the lack of breast development and primary amenorrhoea in females, the majority of cases are detected during puberty.²

Last but not least, patients and, if at all possible, their first-degree relatives should be thoroughly examined for the presence of non-reproductive non-olfactory additional disorders, such as mirror movements, palate anomalies, renal agenesis (ultrasonography), hearing impairment (audiometric testing), and tooth agenesis. This is because these abnormalities can point the geneticist in the direction of specific genetic forms of the disease. Sometimes KS is discovered before birth in families with cleft palate or renal agenesis identified by foetal ultrasonography.²

However, only KAL2 patients have been found to suffer external ear hypoplasia, nasal cartilage loss, and hand or foot skeletal abnormalities.

Although the severity varies between KAL1 (high arched palate) and KAL2 (cleft palate), palate deformities should also be regarded as one of these common characteristics. Up to 25–30% of KAL2 instances may result in cleft lip and/or palate.²

Treatment

Hypogonadism (hormone replacement therapy) is the treatment for KS. Currently, there is no cure for olfactory deficiency. Hormone replacement treatments are used to promote the development of secondary sexual traits throughout puberty and thereafter to induce conception in both sexes.²

A multidisciplinary approach to patient management is required because of the broad and multisystem nature of KS, comprising of geneticists, neurologists, otolaryngologists, endocrinologists, and reproductive experts. Addressing the many demands and possible problems linked to this disorder requires early detection and specific treatment.

Early management can maximise long-term results, especially in terms of pubertal growth, fertility, and bone health; thus, prompt and correct diagnosis is essential.
Effective management of KS and the prevention of consequences, including delayed puberty, infertility, and problems with bone health, depend on an early and precise diagnosis.⁵

Prevention of osteoporosis and bone health: People with KS are more susceptible to osteoporosis and reduced bone mineral density because of a chronic sex hormone deficit. As a result, maintaining bone health is essential to long-term care. Monitoring bone density: To evaluate bone mineral density, dual-energy X-ray absorptiometry (DEXA) scans are advised, particularly for patients who have had delayed HRT initiation.

Calcium and Vitamin D Supplementation: If dietary intake of Calcium and vitamin D is inadequate, supplementation may be necessary. Adequate intake is essential for bone health.
Weight-bearing exercise: To increase bone strength and general physical fitness, regular weight-bearing and resistance training is advised.⁵

Treatment of cleft lip and palate

Children with cleft abnormalities are best cared for by a specific team of doctors who work with them from diagnosis to adulthood. The lip restoration is typically performed between the ages of two and three months, according to the rule of 10.⁶ Millard's advancement rotation technique is the preferred surgical technique.

Cleft palate repair should take place between the ages of six and twelve months.
When the permanent molars emerge and the cleft tooth buds are nearing eruption. Orthodontics can be used to modify the cleft segment and prepare for the alveolar bone graft. Bone grafting normally occurs between the ages of seven and nine.⁶

Revisions to the lips and nose typically address enlarged scars, vermilion mismatch, shortened lip segments, flattened ala, flattened nasal tip, lip soft tissue scarcity, whistling deformity, and uneven mucosal lip contours.

Conclusion

Diagnostic evaluation often necessitates a multidisciplinary approach that includes genetic testing, hormonal tests, and neuroimaging to confirm the diagnosis and assess related abnormalities. 

Therapeutic strategies largely focus on hormonal replacement therapy to induce and maintain secondary sexual characteristics, as well as fertility treatment alternatives for those seeking reproductive outcomes. Emerging treatments, including the possible use of gene therapy, are being investigated, providing fresh hope for focused interventions.

The introduction of advanced genetic testing, such as next-generation sequencing, has changed the diagnostic landscape, allowing for precise genetic characterisation and boosting our understanding of genotype-phenotype correlations.